Effect of Captopril on Blood Pressure, Total Body Sodium and Fluid Consumption of Genetically Hypertensive (GH) and Normotensive (N) Rats
- 1 January 1981
- journal article
- research article
- Published by Taylor & Francis in Clinical and Experimental Hypertension
- Vol. 3 (6) , 1239-1263
- https://doi.org/10.3109/10641968109037436
Abstract
Captopril was administered in the drinking fluid to normotensive rats and rats of the New Zealand genetically hypertensive (GH) strain. It lowered BP in both strains of rat, particularly in rats deprived of sodium; in these rats BP rose again when the drug was stopped even though there was no access to sodium. Thus captopril appeared to lower blood pressure not by reduction in total exchangeable sodium but by some other. mechanism, presumably inhibition of vasoconstriction. Total exchangeable sodium did not change significantly in rats treated with captopril and having access to salt in the drinking fluid, though it fell in rats deprived of sodium. Captopril caused an increase in fluid intake, particularly intake of 0.5% NaCl solution and this may have compensated for any loss of body sodium. It was not clear whether the thirst for water and the desire for salt were due to effects of captopril in the CNS or were secondary to increased excretion of salt and water.This publication has 11 references indexed in Scilit:
- Effects of captopril (SQ 14, 225) on the renin-angiotensin-aldosterone system in normal ratsEuropean Journal of Pharmacology, 1980
- Prevention of the development of spontaneous hypertension in rats by captopril (SQ 14,225)European Journal of Pharmacology, 1979
- DEVELOPMENT OF ANGIOTENSIN‐CONVERTING ENZYME INHIBITORSThe Medical Journal of Australia, 1979
- The effect of SQ14,225 on systolic blood pressure and urinary excretion of vasopressin in the developing spontaneously hypertensive rat.Hypertension, 1979
- Antihypertensive Effect of Prolonged Blockade of Angiotensin Formation in Benign and Malignant, one- and two-Kidney Goldblatt Hypertensive RatsClinical Science, 1979
- Effect of an angiotensin converting enzyme inhibitor (SQ 14,225) on β-adrenergic and angiotensin-induced thirstsEuropean Journal of Pharmacology, 1979
- EFFECTS OF CHRONIC TREATMENT WITH CAPTOPRIL(SQ 14,225), AN ORALLY ACTIVE INHIBITOR OFANGIOTENSIN I-CONVERTING ENZYME, INSPONTANEOUSLY HYPERTENSIVE RATSThe Japanese Journal of Pharmacology, 1979
- Long-Term Measurement of Total Exchangeable Sodium in One- and Two-Kidney Goldblatt RatsClinical and Experimental Hypertension, 1979
- SQ 14,225 (D-3-MERCAPTO-2-METHYLPROPANOYL-L-PROLINE), A NOVEL ORALLY ACTIVE INHIBITOR OF ANGIOTENSIN I-CONVERTING ENZYME1978
- ANTIHYPERTENSIVE ACTIVITY IN RATS OF SQ 14,225, AN ORALLY ACTIVE INHIBITOR OF ANGIOTENSIN I-CONVERTING ENZYME1978